Filing Flows › Mimedx Group (MDXG) › Q3 2026 › vs Q3 2025
Mimedx Group (MDXG) Q3 2026 vs Q3 2025 (year over year)
Mimedx Group's revenue fell $51.4M (-45%) from $114M in Q3 2025 to $62.3M in Q3 2026. The biggest changes: Wound −$54.8M (-71%); Surgical +$3.3M (+9%).
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.0% | 25.6% | -19.6 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Surgical | $40.0M | $36.6M | $3.3M | +9% |
| Wound | $22.3M | $77.1M | −$54.8M | -71% |
| Revenue | $62.3M | $114M | −$51.4M | -45% |
| Other income, net | $640K | $659K | −$19K | -3% |
| Income tax benefit | $2.4M | −$6.1M | $8.5M | — |
| Net loss | $8.7M | −$16.7M | $25.4M | — |
| Costs & expenses | $74.0M | $114M | −$40.4M | -35% |
| Operating costs | $74.0M | $91.5M | −$17.6M | -19% |
| Cost of revenue | $12.6M | $18.7M | −$6.1M | -33% |
| Research & development | $2.8M | $3.7M | −$907K | -24% |
| Operating cash sources | $12.6M | $12.6M | $21K | +0.2% |
| Depreciation & amortization | $665K | $684K | −$19K | -3% |
| Share-based compensation | $3.2M | $4.9M | −$1.7M | -35% |
| Working capital & other | $8.7M | $7.0M | $1.7M | +25% |
| Net loss absorbed | $8.7M | −$16.7M | $25.4M | — |
| Operating cash flow | $3.9M | $29.3M | −$25.4M | -87% |
| Free cash flow (OCF − capex) | $3.8M | $29.1M | −$25.4M | -87% |
| Capital expenditures | $166K | $192K | −$26K | -14% |
Questions
How much did Mimedx Group's revenue grow year over year in Q3 2026?
Mimedx Group's revenue fell $51.4M (-45%) from $114M in Q3 2025 to $62.3M in Q3 2026.
What drove Mimedx Group's revenue change in Q3 2026?
Wound −$54.8M (-71%); Surgical +$3.3M (+9%).